124 results about "Fusobacteria" patented technology

The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E.Coli, Gemmiger, Desullomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

The invention relates to a method for calculating a flora balanced relation index in an individual excrement sample, and an application of the method in screening, diagnosis or auxiliary diagnosis incolorectal cancer (CRC). By extracting bacteria in excrement during DNA sequencing, the types and quantity characteristics of the bacteria can be obtained, and a CRC diagnosis by taking quantity ratiocharacteristic of a plurality of bacteria as a base is carried out. Compared with the methods used in clinical diagnosis or noninvasive screening of CRC with an applied patent, the method is completely noninvasive, and can realize accurate diagnosis of CRC. The analysis result displays that a ratio of fusobacterium nucleatum Fn to bifidobacteria Bb quantity (Fn/Bb) has high susceptibility and specificity on CRC screening, which can respectively reach 84.6% and 92.3% (AUC=0.911). the ratio of fusobacterium nucleatum Fn to clostridium leptum Fp (Fn/Fp) quantity is combined to increase the diagnosis value on CRC, and the Area Under Curve (AUC) of a subject work characteristic curve can reach 0.943. In addition, combination of Fn/Bb and Fn/Fp quantity ratio for screening I-stage CRC has 60% of specificity and 90% of sensitivity.

The invention discloses an anti-porphyromonas gingivalis and fusobacterium nucleatum compound specific IgY preparation. According to the preparation, 10-70 parts by weight of porphyromonas gingivalis thalli and thalli fragments, and 30-90 parts by weight of fusobacterium nucleatum thalli and thalli fragments are compounded into an antigen to immune an egg laying hen. The invention also discloses the specific preparation method of the anti-porphyromonas gingivalis and fusobacterium nucleatum compound specific IgY preparation, and toothpaste containing the anti-porphyromonas gingivalis and fusobacterium nucleatum compound specific IgY preparation. By the IgY toothpaste which is used for treating and preventing gingivitis and ozostomia has obvious effects in preventing and treating the gingivitis and the ozostomia.

The invention provides a Fusobacterium nucleatum subsp. animalis strain THCT6b3 separated from human intestines. A 16SrRNA gene sequence of the strain is shown in SEQ ID NO:1. The classification nameof the strain is Fusobacterium nucleatum subsp. animalis and collected on May 17, 2019 with the collection number of CCTCC NO:M 2019363 in the China Center for Type Culture Collection. The invention further provides application of the strain in detection of Fusobacterium nucleatum. A PCR-based molecular identification method for Fusobacterium nucleatum subsp. animalis is established for the firsttime. The strain can promote disclosing of composition and sources of the Fusobacterium nucleatum in intestines of colorectal cancer patients, and contributes to analysis of molecular epidemiologic characteristics of the Fusobacterium nucleatum.

The invention discloses primer group information of fusobacterium nucleatum, a quantitative PCR (Polymerase Chain Reaction) detection method and application of primer group and method. According to a16S rRNA (ribosomal Ribonucleic Acid) nucleotide sequence and a BLAST (Basic Local Alignment Search Tool) function of bacteria in an NCBI (National Center of Biotechnology Information) database, a fusobacterium nucleatum related primer and V3 to V4 primers are designed according to primer design software Primer Primer 5, and the primers are identified. Genome information of total bacteria is extracted from an excrement sample; the qPCR (quantitative Polymerase Chain Reaction) is carried out through utilizing the primers and the relative content of the fusobacterium nucleatum is calculated andobtained. The detection method is used as a principle and an intestinal micro-ecological detection kit is prepared by utilizing the fusobacterium nucleatum primer. A kit is used for carrying out actual detection and a result shows that the content of the fusobacterium nucleatum in the excrement samples of an intestinal micro-ecological patient and a patient with intestinal cancer is remarkably different from that of normal people. A specific primer of the fusobacterium nucleatum, a rapid and accurate detection method and research and development of an intestinal micro-ecological kit provide methods for knowing the distribution of an intestinal micro-ecology and predicating and primarily screening diseases.

The invention discloses a colorectal cancer auxiliary diagnosis kit for fecal nucleic acid detection and a use method of the colorectal cancer auxiliary diagnosis kit. The kit comprises a KRAS gene mutation detection reagent, a fusobacterium nucleatum detection reagent, a DNA sulfite conversion reagent and a Septin9, SDC2, HOXA11 and NDRG4 gene methylation detection reagent. The use method comprises the following steps: collecting an excrement sample, and then completing DNA purification, KRAS gene mutation detection, fusobacterium nucleatum abundance detection and Septin9, SDC2, HOXA11 and NDRG4 gene methylation detection of the sample by using reagents in the kit; and calculating the obtained data through a logistic regression model, and performing result evaluation and analysis. The colorectal cancer detection sensitivity reaches 89% or above, the specificity reaches 94% or so, high-sensitivity and high-specificity colorectal cancer detection can be achieved, and doctors can be helped to guide follow-up treatment medication of patients.

The invention relates to the technical field of microorganisms, and discloses lactobacillus plantarum for preventing and/or treating periodontitis as well as a culture, preparation and application of the lactobacillus plantarum. The name of the lactobacillus plantarum is Lactobacillus plantarum CCFM1137, the lactobacillus plantarum is preserved in Guangdong Microbial Culture Collection Center on the 5th floor of the Building 59, No. 100 Courtyard, Xianlie Middle Road, Guangzhou on August 1, 2020, and the preservation number is GDMCC No: 61114. The lactobacillus plantarum can be used for inhibiting the formation of a mixed bacterium biological membrane of porphyromonas gingivalis, prevotella intermedia and fusobacterium nucleatum; the content of inflammatory factors in a periodontitis cell model can be reduced; the expression quantity of transmembrane transport protein in a periodontitis cell model can be increased; and the lactobacillus plantarumcan be used for preventing and/or treating oral diseases and inhibiting prevotella intermedia, porphyromonas gingivalis and/or fusobacterium nucleatum.

The invention provides a fusobacterium nucleatum subsp.animalis strain THCT5A4 separated from human rectal cancer tumor tissue. A classification name is Fusobacterium nucleatum subsp.animalis THCT5A4,a preservation number of the fusobacterium nucleatum subsp.animalis strain THCT5A4 separated from the human rectal cancer tumor tissue is CCTCC NO: M 2019366, the preservation date is May 17th, 2019,the preservation organization is China General Microbiological Culture Collection Center, and a 16SrRNA gene sequence of the fusobacterium nucleatum subsp.animalis strain THCT5A4 separated from the human rectal cancer tumor tissue is shown in SEQ ID NO:1 as shown in the description. A separation method of the fusobacterium nucleatum subsp.animalis strain is provided. A result of co-culture of a colorectal cancer cell line and the THCT5A4 shows that the THCT5A4 can significantly promote proliferation of colorectal cancer cells, therefore, the THCT5A4 can provide diverse in-vitro or in-vivo experimental conditions for simulating an intestinal environment for studies of colorectal cancer, and a colorectal cancer disease model can be built for screening medicines for treating colorectal cancer.

The invention provides a fusobacterium nucleatum polymorphic subspecies isolate THCT15E1, a classification name is Fusobacterium nuucleates subsp.nucleatum THCT15E1, a preservation number of the strain is CCTCC NO: M 2019362, a preservation date is May 17, 2019, a preservation unit is China Center for Type Culture Collection, and the 16SrRNA gene sequence of the strain is shown as SEQ ID NO: 1. The result of co-culture of the colorectal cancer cell line and THCT15E1 shows that THCT15E1 can significantly promote colorectal cancer cell proliferation; therefore, the THCT15E1 can provide diversified experimental conditions for in-vitro or in-vivo intestinal environment simulation for colorectal cancer research, and can also construct a colorectal cancer disease model to screen drugs for treating colorectal cancer.

The invention provides fusobacterium nucleatum THCT14E2 which is obtained from large intestine cancer tumor tissue and does not belong to known fusobacterium nucleatum subsp.vincentii. The 16SrRNA gene sequence of the strain is as shown in SEQID NO:1. The classification designation of the THCT14E2 is Fusobacterium nucleatum, the preservation number is CCTCC NO:M 2019361, the preservation date is May 17th, 2019, and the preservation unit is China Center for Type Culture Collection. The colorectal cancer cell line and THCT14E2 co-culture result shows that the THCT14E2 can significantly promote colorectal cancer cell proliferation. Therefore, the THCT14E2 can promote understanding of micro-ecology diversity of rectum cancer, and facilitate function research of the fusobacterium nucleatum fromthe colorectal cancer.

Decoy nucleic acid sequences comprising a binding site for a target transcription factor, wherein the binding site is not operably linked to a gene, and wherein the transcription factor comprises a regulator of expression of a gene or genes in Clostridium difficile encoding one or more of: (i) a cellular growth factor; (ii) a cellular toxin; (iii) a cellular sporulation factor; (iv) a cellular stress response; and/or (v) a cellular essential gene are described. Uses of the decoys in antibacterial complexes for the treatment of bacterial infections are also described.

A TaqMan/MGB probe PCR (polymerase chain reaction) technology can carry out bacterial genus identification on clostridium difficile in fecal genomes, simultaneously detect the carrying situation of toxin genes, and can judge whether a toxin A has deletion. A fecal specimen is not required to be purely cultured, and the strain identification and the toxin detection are completed in a reaction system. The method has the characteristics of simple operation, good repeatability, high flux detection specimens, short report time, and the like, and is applicable to the screening of pathogenesis of patients with diarrhea caused by clinically unexplained causes. The invention solves the technical problems that fecal specimens can be subjected to strain identification and strain toxin carrying situation screening simultaneously without being purely cultured, and a DNA (deoxyribonucleic acid) detection method for fecal genomes, which is high in sensibility, is provided. Because traditional anaerobic culture is uneasy to perform, and an enzyme immunoassay has methodology defects, according to the invention, the diagnosis rate of clostridium difficile associated diarrhea is significantly increased. Meanwhile, the invention also can be applied to the monitoring of drug used in the process of treating the diseases.

The invention provides a primer compound for identifying intestinal microecological state and an application thereof. The primer compound is a specific primer designed for intestinal bacterium 16S rRNA; the specific primer includes random basic groups; the quantity of random basic groups is 3-5; the intestinal bacterium includes any one of or combination of at least two of symbiotic clostridia, bifidobacterium adolescentis, fusobacterium nucleatum, peptostreptococcus anaerobius or klebsiella. A kit researched and developed on the basis of the primer compound provided by the invention has a specificity for detecting intestinal microecological imbalance reaching up to 92.5% and a sensitivity reaching up to 80.43%.

The invention relates to a clostridium perfringen alpha toxin genetic engineering vaccine and application thereof. The clostridium perfringen alpha toxin genetic engineering vaccine is prepared by designing a specific primer, implementing polymerase chain reaction (PCR) amplification on A-type clostridium perfringen DNA to obtain an alpha toxin gene segment, cloning the gene segment onto a pMD18-T Vector, selecting a positive recon and linking the positive recon onto a PET-28 alpha (+) plasmid; introducing the recombinant plasmid to a receptor strain to successfully construct a recombinant strain BL21 (DE3)-alpha; emulsifying the prepared alpha toxin protein and an aluminum hydroxide adjuvant at a volume ratio of 9:1, and adding 0.01% thiomersal to obtain the clostridium perfringen alpha toxin genetic engineering vaccine. The clostridium perfringen alpha toxin genetic engineering vaccine is easy for realization of industrial production, simple to operate and good in safety, and is capable of effectively preventing such diseases as animal necrotic enteritis, enterotoxemia, and human and animal traumatic gas gangrene caused by the A-type clostridium perfringens.